Precision Study of CLAiR AI Software

Completed · Not applicable

Conditions studied: Cardiovascular Risk

In brief

This multi-site precision study evaluated the performance and reproducibility of the CLAiR artificial intelligence (AI) software in identifying elevated risk of atherosclerotic cardiovascular disease (ASCVD) from retinal fundus images. Participants underwent protocol-defined retinal imaging using Topcon NW400 and NW500 cameras. The study assessed agreement and consistency of device outputs across operators and imaging conditions. No medical management decisions were made based on device results.

Key facts

Study ID
NCT07747233
Run by
Toku Eyes Ltd
People needed
56
Starts
2025-12-05
Expected to finish
2026-01-09
Last updated by the study team
2026-08-05

Who can join

Age: 40 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.